A CD34-CD42b bispecific antibody targets hematopoietic stem cells via CD34 and platelets via CD42b, enabling hematopoietic stem cells to piggyback on platelets to reach sites of myocardial infarction where they can contribute to tissue repair (Fig. 2C).141. The gene discussed is CD34; the disease is myocardial infarction.